Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick M Liu

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Immunology Research|July 16, 2016
Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving ChemotherapyLinglong Zou, Anton Buchner, Martin Roberge, et al.
Bioanalysis|February 21, 2015
Comparative immunogenicity assessment: a critical consideration for biosimilar developmentPatrick M Liu, Linglong Zou, Chanchal Sadhu, et al.
Bioanalysis|July 31, 2018
Immunogenicity assessment of tbo-filgrastim in cancer patients receiving chemotherapyLinglong Zou, Anton Buchner, Jodie A Field, et al.
Bioanalysis|September 29, 2017
Method establishment for discerned immunogenicity assessment of a recombinant glycoprotein containing nonhuman sialic acid Neu5Gc residuesMarc-Olivier Montjovent, Linglong Zou, Heinrich Faust, et al.
BMC Pulmonary Medicine|February 21, 2012
A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndromePeter E Morris, Jay S Steingrub, Bee Y Huang, et al.
Journal of Clinical Pharmacology|June 25, 2015
Differential sensitivity of lipegfilgrastim and pegfilgrastim to neutrophil elastase correlates with differences in clinical pharmacokinetic profileAfsaneh Abdolzade-Bavil, Aaron von Kerczek, Bridget A Cooksey, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Immunology Research|July 16, 2016
Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving ChemotherapyLinglong Zou, Anton Buchner, Martin Roberge, et al.
Bioanalysis|February 21, 2015
Comparative immunogenicity assessment: a critical consideration for biosimilar developmentPatrick M Liu, Linglong Zou, Chanchal Sadhu, et al.
Bioanalysis|July 31, 2018
Immunogenicity assessment of tbo-filgrastim in cancer patients receiving chemotherapyLinglong Zou, Anton Buchner, Jodie A Field, et al.
Bioanalysis|September 29, 2017
Method establishment for discerned immunogenicity assessment of a recombinant glycoprotein containing nonhuman sialic acid Neu5Gc residuesMarc-Olivier Montjovent, Linglong Zou, Heinrich Faust, et al.
BMC Pulmonary Medicine|February 21, 2012
A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndromePeter E Morris, Jay S Steingrub, Bee Y Huang, et al.
Journal of Clinical Pharmacology|June 25, 2015
Differential sensitivity of lipegfilgrastim and pegfilgrastim to neutrophil elastase correlates with differences in clinical pharmacokinetic profileAfsaneh Abdolzade-Bavil, Aaron von Kerczek, Bridget A Cooksey, et al.
Pageof 1